MEDP Medpace Holdings, Inc.

QT69

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

663.00

+14.86+2.29%

Overview Short InterestFilings

MEDPQT69Medpace Holdings, Inc.·NASDAQ

Overview Short InterestFilings

663.00+2.29%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RVTY+12.08%$169.92 CRL+3.42%$350.12 ICLR+1.00%$207.19 GH+3.29%$176.35 DGX-0.41%$249.77 LH-0.01%$355.56 QGEN+0.01%$50.35 MTD+1.96%$1711.15

Snapshot

Index	—	P/E	35.93	EPS (ttm)	18.04	Insider Own	47.38%	Shs Outstand	27.97M	Perf Week	-4.23%

Market Cap	18.13B	Forward P/E	32.91	EPS next Y	19.70	Insider Trans	-2.83%	Shs Float	22.72M	Perf Month	8.12%

Enterprise Value	17.57B	PEG	3.38	EPS next Q	4.82			Short Float	7.10%	Perf Quarter	12.70%

Income	517.00M	P/S	6.39	EPS this Y	23.21%			Short Ratio	5.93	Perf Half Y	55.42%

Sales	2.84B	P/B	30.99	EPS next Y	7.98%	ROA	22.49%	Short Interest	1.61M	Perf YTD	15.40%

Book/sh	20.91	P/C	25.72	EPS next 5Y	10.63%	ROE	99.76%	52W High	693.97 -4.46%	Perf Year	11.68%

Cash/sh	25.20	P/FCF	27.18	EPS past 3/5Y	28.04% 31.81%	ROIC	62.17%	52W Low	373.00 77.75%	Perf 3Y	153.30%

Dividend Est.	—	EV/EBITDA	27.33	Sales past 3/5Y	20.11% 22.26%	Gross Margin	29.14%	Volatility	2.69% 3.45%	Perf 5Y	244.06%

Dividend TTM	—	EV/Sales	6.19	EPS Y/Y TTM	26.07%	Oper. Margin	21.39%	ATR (14)	20.86	Perf 10Y	1970.73%

Dividend Ex-Date	—	Quick Ratio	0.83	Sales Y/Y TTM	20.31%	Profit Margin	18.24%	RSI (14)	53.25	Recom	2.79

Dividend Gr. 3/5Y	—	Current Ratio	0.83	EPS Q/Q	25.39%	SMA20	1.56%	Beta	1.09	Target Price	646.90

Payout	0.00%	Debt/Eq	0.25	Sales Q/Q	8.48%	SMA50	4.59%	Rel Volume	0.77	Prev Close	648.14

Employees	6,500	LT Debt/Eq	0.25	Earnings	Feb 08	SMA200	22.40%	Avg Volume	258.07K	Price	663.00

IPO Date	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.11% 0.21%	Net Debt/EBITDA	-0.87	Volume	198,552	Change	2.29%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-26-26	Reiterated	BMO Capital	Market Perform	$600 → $670
Oct-23-26	Reiterated	Mizuho Securities	Outperform	$700 → $730
Oct-23-26	Reiterated	Robert W. Baird		$638 → $699
Oct-23-26	Reiterated	Barclays	Equal Weight	$625 → $675
Oct-23-26	Reiterated	Truist Securities	Hold	$539 → $633
Oct-23-26	Reiterated	UBS	Neutral	$673 → $700
Oct-07-26	Reiterated	Barclays	Equal Weight	$600 → $625
Oct-07-26	Reiterated	Mizuho	Outperform	$665 → $700
Sep-30-26	Upgrade	UBS	Sell → Neutral	$452 → $673
Jul-24-26	Reiterated	Robert W. Baird		$547 → $624

Latest News· Times ET

Nov-02-26

Nov-02-2612:41PM

CON vs. MEDP: Which Stock Is the Better Value Option?zacks.com

08:17AM

IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-MarketYahoo

Oct-30-26

Oct-30-2601:01PM

Medpace (MEDP) is a Great Momentum Stock: Should You Buy?zacks.com

Oct-29-26

Oct-29-2610:16AM

Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?zacks.com

Oct-26-26

Oct-26-2601:46PM

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"zacks.com

01:01PM

All You Need to Know About Medpace (MEDP) Rating Upgrade to Buyzacks.com

10:46AM

Here's Why Medpace (MEDP) is a Strong Growth Stockzacks.com

09:25AM

BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $670Benzinga

Oct-25-26

Oct-25-2610:02AM

Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rateseekingalpha.com

Oct-22-26

Oct-22-2611:51PM

Medpace: 3 Key Takeaways for Long-Term Investorsfool.com

11:47AM

Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcriptseekingalpha.com

11:06AM

Medpace Q3 Earnings Call Highlightsmarketbeat.com

Oct-21-26

Oct-21-2606:51PM

Medpace (MEDP) Q3 Earnings and Revenues Beat Estimateszacks.com

05:57PM

A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.48gurufocus.com

04:53PM

Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlookinvestors.com

Company

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	2,838	2,530	2,109	1,886	—	—	—	—	—
Cost of Goods Sold Incl. D&A	2,011	1,770	1,453	1,361	—	—	—	—	—
Gross Profit	827	761	656	525	—	—	—	—	—
Selling, General and Administrative Excl. Other	193	198	180	161	—	—	—	—	—
Research and Development	0	0	0	0	—	—	—	—	—
Other Operating Expense	27	28	29	27	—	—	—	—	—
Operating Income	608	535	447	337	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	20	7	29	-1	—	—	—	—	—
Net Income Before Taxes	628	542	476	336	—	—	—	—	—
Income Taxes	109	91	72	53	—	—	—	—	—
Consolidated Net Income	517	451	404	283	—	—	—	—	—
Net Income From Continuing Operations	517	451	404	283	—	—	—	—	—
Net Income	517	451	404	283	—	—	—	—	—
EPS (Recurring)	18.36	15.64	13.06	9.20	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	18.36	15.64	13.06	9.20	—	—	—	—	—
EPS (Diluted)	18.04	15.28	12.63	8.88	—	—	—	—	—
EBITDA	643	571	505	362	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	36.75	36.76	26.30	34.52	—	—	—	—	—
Price To Sales Ratio	6.54	6.44	4.88	5.04	—	—	—	—	—
Gross Margin	29.14	30.08	31.10	27.84	—	—	—	—	—
Operating Margin	21.42	21.15	21.19	17.87	—	—	—	—	—
Net Margin	18.22	17.83	19.16	15.01	—	—	—	—	—
Shares Outstanding	28	29	31	31	—	—	—	—	—
Market Capitalization	18,564	16,288	10,299	9,502	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EWALD STEPHEN P	General Counsel & Corp. Secy.	Oct 29 '26	Sale	690.00	1,245	859,050	19,098	Nov 02
BURWIG SUSAN E	Exec. VP, Operations	Oct 27 '26	Sale	677.00	3,940	2,667,380	54,012	Oct 28
BURWIG SUSAN E	Exec. VP, Operations	Oct 26 '26	Sale	677.00	16,060	10,872,620	57,624	Oct 28
BURWIG SUSAN E	Exec. VP, Operations	Oct 26 '26	Option Exercise	166.73	328	54,687	57,952	Oct 28
BURWIG SUSAN E	Exec. VP, Operations	Oct 21 '26	Option Exercise	166.73	2,700	450,171	73,684	Oct 23
BURWIG SUSAN E	Exec. VP, Operations	Oct 12 '26	Option Exercise	166.73	3,000	500,190	70,984	Oct 14
BURWIG SUSAN E	Exec. VP, Operations	Oct 07 '26	Option Exercise	166.73	2,000	333,460	67,984	Oct 09
McCarthy Cornelius P. III	Director	Sep 30 '26	Option Exercise	0.00	28	0	12,303	Oct 02
Kraft Robert O.	Director	Sep 30 '26	Option Exercise	0.00	32	0	987	Oct 02
Carley Brian T	Director	Sep 30 '26	Option Exercise	0.00	36	0	27,861	Oct 02
Troendle August J.	President & CEO	Sep 30 '26	Sale	625.47	21,966	13,739,074	338,225	Oct 01
Troendle August J.	President & CEO	Sep 29 '26	Sale	621.02	26,701	16,581,855	360,191	Oct 01
Troendle August J.	President & CEO	Sep 28 '26	Sale	620.07	2,410	1,494,369	386,892	Sep 29
Troendle August J.	President & CEO	Sep 25 '26	Sale	620.60	154	95,572	389,302	Sep 29
Troendle August J.	President & CEO	Sep 24 '26	Sale	621.33	27,833	17,293,478	389,456	Sep 25

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.